IMAGIO Consortium Receives Innovative Health Initiative EUR 24 Million Grant to Improve Cancer Treatments

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that the Philips-coordinated IMAGIO consortium [1] of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners [2], to carry out research into less invasive cancer treatments. Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas. Leading European hospitals participating in the consortium include Leiden, Maastricht, Radboud and Utrecht University Medical Centers in the Netherlands and University Hospital of Cologne in Germany.

In Europe about 2.7 million people are diagnosed with cancer each year [3]. While significant advances have been made in treatment, many approaches continue to have negative side effects, impacting healthy tissues as well as targeting the cancer itself. The aim of interventional oncology is the very precise treatment of cancer cells with small instruments supported by imaging modalities such as MRI, ultrasound and CT. Treatment is carried out through targeted surgery, radiotherapy, chemotherapy, immunotherapy, or high-intensity focused ultrasound. In addition to reducing damage to healthy tissues, expanding the use of minimally or non-invasive procedures also decreases the need for major surgery.

"By bringing together leading university medical centers, academic partners, patient and healthcare professional organizations, as well as smaller and larger companies in the medical technology and pharmaceutical industry, the IMAGIO consortium has the potential to make a significant impact on improving cancer treatment," said Bert van Meurs, Chief Business Leader Image Guided Therapy and Chief Business Leader Precision Diagnosis (ad interim) at Royal Philips. "We've chosen to focus on liver and lung cancer - two leading causes of death - alongside soft tissue sarcomas, a highly aggressive form of cancer that affects a significant proportion of young individuals, causing a lot of human suffering. By advancing established treatments and developing new approaches, we aim to improve clinical outcomes."

Specific projects taking place in the consortium include:

  • Collaboration with Radboud University Medical Center and other partners including Jansen Pharmaceutica, Pfizer, Flash Pathology, VU, ETH, ImaginAb Inc. and Eberhards Karls University Tübingen to further expand diagnosis and minimally invasive treatment of lung cancer supported by Philips' Azurion image-guided therapy platform. Read more.
  • Collaboration with Leiden and Maastricht University Medical Centers to improve the diagnosis and treatment of liver cancer using CT, ultrasound, precision marking and ablation technology.
  • Collaboration with University Medical Center Utrecht and TU Delft to improve the treatment of liver cancer through radioembolization (a type of radiation therapy) supported by hybrid imaging modalities. Read more.
  • Collaboration between University Hospital of Cologne, Profound Medical and Philips to treat soft tissue sarcomas with MR-guided high intensity focused ultrasound (MR-HIFU) in combination with Thermosome's lead drug candidate THE001, which is a thermosensitive liposomal formulation of doxorubicin developed in soft tissue sarcoma.

This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112053. The JU receives support from the European Union’s Horizon Europe research and innovation program and life science industries represented by COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries.

1. The IMAGIO consortium - IMaging and Advanced Guidance for workflow optimization in Interventional Oncology - includes the following partners Philips, UMC Utrecht, LUMC, University Hospital of Cologne, TU Delft, Radboudumc, Luxium Solutions, Flash Pathology, Vrije Universiteit Amsterdam, Profound Medical, Gremse-IT, Thermosome, MUMC+, Nederlandse Leverpatiënten Vereniging, Fondazione IRCCS Istituto Nazionale Dei Tumori, Eberhards Karls University Tübingen, European Cancer Patient Coalition, Stichting Longkanker Nederland, ImaginAb Inc., Pfizer Inc., Universiteit Twente, Nanovi, Turku University Hospital, SIOP Europe, Janssen Pharmaceutica; and associated partners Eidgenössische Technische Hochschule Zürich and The Newcastle Upon Tyne Hospitals NHS Foundation Trust.
2. The industry partners are members of COCIR, EFPIA, EuropaBio and MedTech Europe.
3. European Commission, Europe's Beating Cancer Plan https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf.

Most Popular Now

Integrating Care Records is Good. Using …

Opinion Article by Dr Paul Deffley, Chief Medical Officer, Alcidion. A single patient record already exists in the NHS. Or at least, that’s a perception shared by many. A survey of...

Should AI Chatbots Replace Your Therapis…

The new study exposes the dangerous flaws in using artificial intelligence (AI) chatbots for mental health support. For the first time, the researchers evaluated these AI systems against clinical standards...

AI could Help Pathologists Match Cancer …

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators, suggests that artificial intelligence (AI) could significantly improve how...

AI Detects Early Signs of Osteoporosis f…

Investigators have developed an artificial intelligence-assisted diagnostic system that can estimate bone mineral density in both the lumbar spine and the femur of the upper leg, based on X-ray images...

AI Tool Detects Surgical Site Infections…

A team of Mayo Clinic researchers has developed an artificial intelligence (AI) system that can detect surgical site infections (SSIs) with high accuracy from patient-submitted postoperative wound photos, potentially transforming...

AI Sharpens Pathologists' Interpret…

Pathologists' examinations of tissue samples from skin cancer tumours improved when they were assisted by an AI tool. The assessments became more consistent and patients' prognoses were described more accurately...

Meet Your Digital Twin

Before an important meeting or when a big decision needs to be made, we often mentally run through various scenarios before settling on the best course of action. But when...

NHS National Rehabilitation Centre to De…

The new NHS National Rehabilitation Centre will deploy technology to help patients to maintain their independence as they recover from life-changing injuries and illnesses and regain quality of life. Airwave Healthcare...

AI Finds Hundreds of Potential Antibioti…

Snake, scorpion, and spider venom are most frequently associated with poisonous bites, but with the help of artificial intelligence, they might be able to help fight antibiotic resistance, which contributes...

AI Tool Accurately Detects Tumor Locatio…

An AI model trained to detect abnormalities on breast MR images accurately depicted tumor locations and outperformed benchmark models when tested in three different groups, according to a study published...

AI can Accelerate Search for More Effect…

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in...

AI Accurately Classifies Pancreatic Cyst…

Artificial intelligence (AI) models such as ChatGPT are designed to rapidly process data. Using the AI ChatGPT-4 platform to extract and analyze specific data points from the Magnetic Resonance Imaging...